Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer

Clinical Colorectal Cancer
Eric O GamboaNairmeen Haller

Abstract

Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing vascular endothelial growth factor. Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism. We present a case of a 67-year-old man who developed Fournier's gangrene during treatment with bevacizumab 4 months after completing mFOLFOX6 (5-FU/leucovorin/oxaliplatin) for CRC. Other than bevacizumab, the patient had no medications and had no medical conditions that would predispose to Fournier's gangrene.

References

Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jun 5, 2004·The Oncologist·Napoleone Ferrara
Oct 8, 2004·Nature Biotechnology·Mark Ratner
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Aug 25, 2005·Journal of Surgical Oncology·Frank A ScappaticciHerbert Hurwitz
Jan 10, 2006·ANZ Journal of Surgery·Fadil AyanFeridun Sirin
Mar 6, 2009·The Annals of Pharmacotherapy·Sarah M Gressett, Sachin R Shah

❮ Previous
Next ❯

Citations

Aug 22, 2013·World Journal of Gastroenterology : WJG·Efstathios T Pavlidis, Theodoros E Pavlidis
May 23, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Behrooz K ShamlooSheila Weiss Smith
Jan 22, 2014·Clinical Genitourinary Cancer·Jolanta PiszczekStefan Urbanski
Nov 21, 2015·Journal of the Academy of Nutrition and Dietetics·Junko UeshimaHayao Nakatani
May 25, 2011·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·E T PavlidisA K Sakantamis
Apr 2, 2019·Biological & Pharmaceutical Bulletin·Tetsuya NomuraNaoki Utoguchi
Aug 5, 2017·Annals of the Royal College of Surgeons of England·A Gonzaga-LópezA Ruiz-Casado
Apr 28, 2020·Molecular and Clinical Oncology·Martina BaroneRosa Falcone
Sep 3, 2020·Therapeutic Advances in Drug Safety·Zoran RakusicIvica Sjekavica

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

British Journal of Nursing : BJN
Liesbeth LemmensMaggie Uzzell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Fairooz KabbinavarWilliam F Novotny
Issues in Emerging Health Technologies
A Hadj Tahar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Fairooz KabbinavarEmily Bergsland
© 2021 Meta ULC. All rights reserved